Get the Stockscreener App
0.7952
5.32%
-0.0447
Atossa Therapeutics Inc stock is traded at $0.7952, with a volume of 559.43K.
It is down -5.32% in the last 24 hours and down -8.59% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.8399
Open:
$0.85
24h Volume:
559.43K
Relative Volume:
0.67
Market Cap:
$100.04M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.6145
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-4.22%
1M Performance:
-8.59%
6M Performance:
-42.79%
1Y Performance:
-21.27%
1-Day Range:
$0.7901
$0.85
1-Week Range:
$0.7901
$0.885
52-Week Range:
$0.7203
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7952 | 100.04M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World
Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex
Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily
Atossa Therapeutics faces patent setback, continues development - MSN
FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat
Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan
Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News
Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex
Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Given "Buy" Rating at HC Wainwright - MarketBeat
JPMorgan Chase & Co. Acquires 95,643 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.75 - MSN
Atossa Genetics stock hits 52-week low at $0.75 By Investing.com - Investing.com Australia
Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen - Marketscreener.com
Troy Minerals Inc. (TROY-CN) QuotePress Release - The Globe and Mail
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent - GlobeNewswire
Atossa's Patent Strategy Shift: New Endoxifen Patent Reinforces 118+ Protected Claims - StockTitan
Option Volatility And Earnings Report For January 2731 - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - The Manila Times
Atossa Therapeutics reports progress in breast cancer treatments By Investing.com - Investing.com South Africa
Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC - Defense World
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):